PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety

(2016) Thomas S. Y. Chan et al.   ANNALS OF HEMATOLOGY

Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma

(2016) A K Singh et al.   BONE MARROW TRANSPLANTATION

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation

(2016) J A Yared et al.   BONE MARROW TRANSPLANTATION

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Immune checkpoint blockade in hematologic malignancies

(2015) P. Armand   BLOOD

An update of current treatments for adult acute myeloid leukemia

(2015) H. Dombret et al.   BLOOD

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

(2015) T Sauer et al.   BONE MARROW TRANSPLANTATION

Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation

(2015) L Angenendt et al.   BONE MARROW TRANSPLANTATION

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change

(2013) Maximilian Christopeit et al.   JOURNAL OF CLINICAL ONCOLOGY

Relapse after allogeneic stem cell transplantation

(2010) A John Barrett et al.   Expert Review of Hematology